Zobrazeno 1 - 10
of 31
pro vyhledávání: '"I. Torre Salaberri"'
Autor:
J. L. Martín-Varillas, L. Sanchez-Bilbao, V. Calvo-Río, A. Adan, I. Hernanz Rodriguez, E. Beltrán, S. Castro, P. Fanlo Mateo, A. García Martos, I. Torre-Salaberri, M. Cordero-Coma, J. De Dios-Jiménez Aberásturi, Á. García-Aparicio, M. Hernández-Garfella, A. Sanchez-Andrade, A. García-Valle, R. Miguélez, O. Maiz, S. Rodríguez Montero, A. Urruticoechea-Arana, R. Veroz Gonzalez, A. Conesa, C. Fernández-Carballido, V. Jovani, O. Martínez González, P. Moya, S. Romero-Yuste, P. Rubio Muñoz, E. Peña Sainz-Pardo, M. Garijo Bufort, J. L. Hernández, R. Blanco
Publikováno v:
Annals of the Rheumatic Diseases. 81:1013.2-1014
BackgroundAdalimumab remains the only biologic approved by the EMA and FDA for the treatment of non-infectious uveitis [1-6]. The reports on efficacy of other anti-TNF drugs such as Certolizumab Pegol (CZP) are scarce.Objectivesto determine the effic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3b04beb95dc0d936b205cfb986e0969c
https://doi.org/10.1136/annrheumdis-2022-eular.3049
https://doi.org/10.1136/annrheumdis-2022-eular.3049
Autor:
L. Sanchez-Bilbao, V. Calvo-Río, J. L. Martín-Varillas, I. Torre-Salaberri, O. Maiz, E. Beltrán, J. L. Álvarez Vega, C. Álvarez-Reguera, R. Demetrio-Pablo, M. A. González-Gay, R. Blanco
Publikováno v:
Annals of the Rheumatic Diseases. 81:1761.2-1762
BackgroundInflammatory ocular pathology (IOP) includes internal and external involvement. IOP may be severe ocular conditions refractory to conventional immunosuppressants and even biological therapy. Janus Kinase inhibitors (JAKINIB) had shown effic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c789a53a7792aa6f7b2a99c92cc69212
https://doi.org/10.1136/annrheumdis-2022-eular.3937
https://doi.org/10.1136/annrheumdis-2022-eular.3937
Autor:
A. Herrero-Morant, J. L. Martín-Varillas, S. Castañeda, O. Maiz-Alonso, J. Sanchez-Martin, N. Ortego, E. Raya, Á. Prior-Español, C. Moriano, R. Melero, J. Graña, A. Urruticoechea-Arana, A. Ramos Calvo, M. Loredo Martínez, E. Salgado-Pérez, F. Sivera, I. Torre-Salaberri, J. Narváez, J. L. Andréu Sánchez, O. Martínez González, R. Gómez de la Torre, S. Fernández, S. Romero-Yuste, I. Gonzalez-Mazon, C. Álvarez-Reguera, D. Martínez-López, J. L. Hernández, M. Á. González-Gay, R. Blanco
Publikováno v:
Annals of the Rheumatic Diseases. 81:704.3-705
BackgroundOcular and Neurobehçet’s Disease (NBD) are the most severe manifestations of Behcet’s disease (1-4). NBD can be classified as a) primary neural parenchymal lesions, also known as parenchymal NBD (p-NBD) or b) secondary to vascular invo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::857714b3bac2534b5074890a939665e9
https://doi.org/10.1136/annrheumdis-2022-eular.2681
https://doi.org/10.1136/annrheumdis-2022-eular.2681
Autor:
M. L. García-Vivar, N. Rivera, E. Galíndez-Agirregoikoa, E. Cuende, A. R. Intxaurbe Pellejero, J. M. Blanco Madrigal, L. Vega, C. García, M. Enjuanes, M. J. Allande, O. B. Fernandez Berrizbeitia, R. Exposito, M. E. Ruiz Lucea, I. Torre-Salaberri
Publikováno v:
Annals of the Rheumatic Diseases. 81:1087.1-1087
BackgroundThe use of telehealth in the control of rheumatic diseases had been scarce, but COVID pandemic forced rheumatologists to try alternatives to classic face-to-face consultation. In times of lockdown phone calls and video calls were easy to pe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1d36ef50e13f756cae922fffe4a4bc45
https://doi.org/10.1136/annrheumdis-2022-eular.3507
https://doi.org/10.1136/annrheumdis-2022-eular.3507
Autor:
Marcelino Revenga, Valvanera Pinillos, Ángel García-Aparicio, Margarita Sánchez-Orgaz, Vanesa Calvo-Río, L. Sanchez-Bilbao, Belén Atienza-Mateo, Santos Castañeda, Ricardo Blanco, Elia Valls-Pascual, Beatriz Valls-Espinosa, Ana Blanco, Ángel Mora, José L. Hernández, Verónica Rodriguez-Mendez, Eva Tomero, D. Martínez-López, Diana Peiteado, Vega Jovaní, I. González-Mazón, O. Maiz-Alonso, M. Fernandez-Prada, Arantxa Conesa, Raúl Veroz-González, Juan A. Troyano, Miguel A. González-Gay, Elena Aurrecoechea, R. Demetrio-Pablo, I. Torre-Salaberri, Ángel López-Vázquez, Francisco J. Toyos-Sáenz de Miera
Publikováno v:
Journal of Clinical Medicine
Volume 9
Issue 9
r-FISABIO. Repositorio Institucional de Producción Científica
instname
Journal of Clinical Medicine, Vol 9, Iss 2816, p 2816 (2020)
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
Journal of clinical medicine 2020, 9, 2816
Biblos-e Archivo. Repositorio Institucional de la UAM
UCrea Repositorio Abierto de la Universidad de Cantabria
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Biblos-e Archivo: Repositorio Institucional de la UAM
Universidad Autónoma de Madrid
Volume 9
Issue 9
r-FISABIO. Repositorio Institucional de Producción Científica
instname
Journal of Clinical Medicine, Vol 9, Iss 2816, p 2816 (2020)
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
Journal of clinical medicine 2020, 9, 2816
Biblos-e Archivo. Repositorio Institucional de la UAM
UCrea Repositorio Abierto de la Universidad de Cantabria
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Biblos-e Archivo: Repositorio Institucional de la UAM
Universidad Autónoma de Madrid
Graves&rsquo
orbitopathy (GO) is the most common extrathyroidal manifestation of Graves&rsquo
disease (GD). Our aim was to assess the efficacy and safety of Tocilizumab (TCZ) in GO refractory to conventional therapy. This was an open-label
orbitopathy (GO) is the most common extrathyroidal manifestation of Graves&rsquo
disease (GD). Our aim was to assess the efficacy and safety of Tocilizumab (TCZ) in GO refractory to conventional therapy. This was an open-label
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15f789ce5ae225e276e6ce4b5e7a12dd
Autor:
M. A. González-Gay, A. Ramos Calvo, J. Sanchez, Susana Romero-Yuste, Águeda Prior-Español, J.L. Andreu Sánchez, S. Castañeda, José Luis Martín-Varillas, Clara Moriano, J.A. Narváez, Norberto Ortego, Roman Blanco, Jenaro Graña, E. Salgado-Pérez, C. Delgado Beltrán, S. Fernández, Aracelys Blanco, E. Diez Alvarez, O. Maíz, O. Martínez González, I. González-Mazón, Enrique Raya, R. Gómez de la Torre, A. Herrero-Morant, Rafael Melero, Alvaro Seijas-Lopez, M. Loredo Martínez, Ana Urruticoechea-Arana, Francisca Sivera, Georgina Espinosa, I. Torre-Salaberri, A. Olivé, Anahy Brandy-Garcia
Publikováno v:
Annals of the Rheumatic Diseases. 80:967-968
Background:Neuro-Behçet’s disease (NBD) is a severe complication of Behcet’s disease (BD). Despite well-established therapies with glucocorticoids and conventional immunosuppressants (cIS), a significant proportion of patients are refractory.Obj
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::974fb8a4e6c2e85970c3a3f9cfc9381d
https://doi.org/10.1136/annrheumdis-2021-eular.3407
https://doi.org/10.1136/annrheumdis-2021-eular.3407
Autor:
Marcelino Revenga, Vanesa Calvo-Río, José L. Hernández, Elia Valls-Pascual, Santos Castañeda, Ricardo Blanco, M. Fernández, M. A. González-Gay, R. Veroz Gonzalez, F. J. Toyos Sáenz de Miera, Andrés Mora, O. Maiz-Alonso, Monica Calderón-Goercke, Arantxa Conesa, Beatriz Valls-Espinosa, Verónica Rodriguez-Mendez, Valvanera Pinillos, Diana Peiteado, José Luis Martín-Varillas, Belén Atienza-Mateo, Vega Jovani, I. González-Mazón, Ana Blanco, E. Tomero Muriel, Ángel García-Aparicio, Elena Aurrecoechea, R. Demetrio-Pablo, I. Torre-Salaberri, Diana Prieto-Peña, Juan A. Troyano, L. Sanchez-Bilbao, Margarita Sánchez-Orgaz, D. Martínez-López
Publikováno v:
Annals of the Rheumatic Diseases. 79:850-851
Background:Tocilizumab (TCZ) has shown promising results in the treatment of inflammatory ocular disease, especially in uveitis (1-3). Graves orbitopathy (GO) is the most common complication of Graves’ disease (GD). Conventional immunosuppressive d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2b681cf03020ef7538a67b891361b097
https://doi.org/10.1136/annrheumdis-2020-eular.3651
https://doi.org/10.1136/annrheumdis-2020-eular.3651
Autor:
Ricardo Blanco, José Luis Andréu Sánchez, Rafael Melero, Susana Romero-Yuste, Olga Martínez González, Esther Vicente, Eva Salgado-Pérez, Angel Ramos Calvo, I. González-Mazón, Ricardo Gómez de la Torre, Anahy Brandy-Garcia, Clara Moriano, Santos Castañeda, José Luis Martín-Varillas, Francisca Sivera, Ana Urruticoechea-Arana, Concepción Delgado Beltrán, Belén Atienza-Mateo, José Luis Callejas-Rubio, Julio Sánchez, Monica Calderón-Goercke, I. Torre-Salaberri, Miguel A. González-Gay, Marta Loredo Martínez, O. Maíz, Elvira Álvarez, Enrique Raya, Vanesa Calvo-Río, Sabela Fernández, J.A. Narváez, Diana Prieto-Peña, Norberto Ortego, Lara Sánchez Bilbao, Alejandro Olivé
Publikováno v:
Saturday, 15 June 2019.
Background: Behcet’s disease (BD) is a variable vessel vasculitis and typically presents with mucocutaneous involvement. However, any organ can be affected, being the neurological affectation (neurobehcet, NB) one of the most serious manifestations
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::06ea2f1e9b1532c6e67de27a0102d563
https://doi.org/10.1136/annrheumdis-2019-eular.7591
https://doi.org/10.1136/annrheumdis-2019-eular.7591
Autor:
Iván Ferraz-Amaro, I. Torre-Salaberri, Vanesa Calvo-Río, O. Maiz-Alonso, Aracelys Blanco, J. Cañal, M. A. González-Gay, L. Domínguez, José Luis Martín-Varillas, S. Muñoz Fernandez, L. Sanchez-Bilbao, Alex Fonollosa, N. Vegas-Revenga, R. Demetrio-Pablo, Miguel Cordero-Coma, M. Agudo-Bilbao, F. Francisco, Norberto Ortego, S. Castañeda, Roman Blanco, J. Ventosa, Manuel Díaz-Llopis, I. González-Mazón, M. D. M. Esteban-Ortega, Eulalia María Beltrán
Publikováno v:
Annals of the Rheumatic Diseases. 80:1412.1-1412
Background:Rapid and effective remission-inducing therapy is mandatory in uveitis to avoid irreversible structural and functional damage. In some severe cases biological agents might be required (1-6).High-dose intravenous methylprednisolone (IVMP) m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d834d044ffa70f07365a464268006e00
https://doi.org/10.1136/annrheumdis-2021-eular.2159
https://doi.org/10.1136/annrheumdis-2021-eular.2159
Autor:
Ana Urruticoechea-Arana, I. Torre-Salaberri, Susana Romero-Yuste, Sheila Castro, Ricardo Blanco, P. Rubio Muñoz, P. Fanlo, José L. Hernández, Á. García Martos, Cristina Fernández-Carballido, O. Martínez González, L. Sanchez-Bilbao, A. García-Valle, J. De Dios-Jiménez Aberásturi, A. Sanchez-Andrade, Miguel Cordero-Coma, Vega Jovani, Marisa Hernández-Garfella, E. Peña Sainz-Pardo, P. Moya, I. González-Mazón, O. Maíz, José Luis Martín-Varillas, Ángel García-Aparicio, R. Veroz Gonzalez, S. Rodríguez Montero, Vanesa Calvo-Río, Emma Beltrán, I. Hernanz Rodríguez, Arantxa Conesa, Alfredo Adán, R. Miguélez, A. Gallego, M. A. González-Gay
Publikováno v:
Annals of the Rheumatic Diseases. 80:952-952
Background:Prognosis of non-infectious refractory uveitis has improved markedly with biologic therapy (BT) (1-5). Most data are with monoclonal anti-TNF drugs, especially Adalimumab (ADA) and Infliximab (IFX). However, there is not enough evidence fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::714cc97adeba7e97293c74c984079fdb
https://doi.org/10.1136/annrheumdis-2021-eular.1233
https://doi.org/10.1136/annrheumdis-2021-eular.1233